Search

Overview of EHA's Hemoglobinopathies Initiatives

The EHA Topics-in-Focus Hemoglobinopathies Program  (focus on Sickle Cell Disease) aims to expand awareness and education about these increasingly common genetic diseases in Europe, among healthcare professionals, patients and the general population.

Read more

Dates and deadlines

You may find in this page all the dates and deadlines related to the EHA2025 Congress.  All deadlines, except if mentioned differently, end at 23:59 CET/CEST.  

The timelines will be updated regularly.

Read more

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

SWG Grant-funded projects, 2025

In November and December 2024, SWGs were invited to develop project ideas and apply for a 2025 SWG Grant. For the 2025 call, EHA offered five grants, each worth €30,000.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more